Holen Sie sich die Stockscreener-App
8.19
3.65%
-0.31
Schlusskurs vom Vortag:
$8.50
Offen:
$8.51
24-Stunden-Volumen:
783.04K
Relative Volume:
0.20
Marktkapitalisierung:
$584.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-2.4818
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-6.08%
1M Leistung:
-13.88%
6M Leistung:
+228.92%
1J Leistung:
+235.66%
1-Tages-Spanne:
$8.055
$8.51
1-Wochen-Bereich:
$8.055
$9.1293
52-Wochen-Spanne:
$0.783
$10.55
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(760) 407-6511
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
8.19 | 606.55M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - PR Newswire
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 11% Over the Past Week - 富途牛牛
VTYX Investor Notice: Levi & Korsinsky Investigates Ventyx Biosciences, Inc. for Securities Law Violations - ACCESS Newswire
Ventyx shares drop after pushing back Phase 2 interim results to early 2026 - MSN
Ventyx Biosciences (NASDAQ:VTYX) Trading 12.3% HigherHere's Why - MarketBeat
Affinity Asset Advisors LLC Invests $9.71 Million in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Shares Gap DownShould You Sell? - MarketBeat
Ventyx Biosciences, Inc. $VTYX Shares Sold by Sio Capital Management LLC - MarketBeat
Ventyx strengthens advisory board, expands phase 2 pericarditis study By Investing.com - Investing.com Nigeria
Ventyx Biosciences Announces Appointment to Advisory Board - marketscreener.com
Ventyx provides clinical and corporate updates - marketscreener.com
Ventyx Provides Clinical And Corporate Updates - TradingView
Ventyx Biosciences Expands Phase 2 Recurrent Pericarditis Study Into Canada, EU, UK - marketscreener.com
Ventyx stock falls after delaying trial data to Q1 2026 By Investing.com - Investing.com Canada
Ventyx strengthens advisory board, expands phase 2 pericarditis study - Investing.com
Ventyx Provides Clinical and Corporate Updates - The Manila Times
Ventyx adds advisors and delays trial data to Q1 2026 - StreetInsider
Institutional owners may ignore Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) recent US$77m market cap decline as longer-term profits stay in the green - simplywall.st
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Ventyx Biosciences, Inc. (VTYX) latest stock news and headlines - Yahoo Finance UK
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Reviewing Tharimmune (NASDAQ:THAR) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Reaches New 1-Year HighTime to Buy? - MarketBeat
With 57% ownership, Ventyx Biosciences, Inc. (NASDAQ:VTYX) boasts of strong institutional backing - Yahoo Finance
Catalyst Funds Management Pty Ltd Invests $61,000 in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data - MSN
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know - MSN
Ventyx Biosciences (NASDAQ:VTYX) Reaches New 12-Month HighTime to Buy? - MarketBeat
Will Ventyx Biosciences Inc. stock see insider buyingTrade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Does Ventyx Biosciences Inc. stock trade at a discount to peersMarket Volume Report & Weekly High Return Forecasts - newser.com
Is Ventyx Biosciences Inc. stock attractive for growth ETFsJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How Ventyx Biosciences Inc. stock reacts to bond yieldsJuly 2025 Analyst Calls & Verified Momentum Stock Ideas - newser.com
Ventyx Biosciences (VTYX) Price Target Increased by 12.94% to 13.99 - MSN
Market reaction to Ventyx Biosciences Inc.’s recent newsGold Moves & Safe Capital Investment Plans - newser.com
Can Ventyx Biosciences Inc. stock double in next 5 years2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
[Form 4] Ventyx Biosciences, Inc. Insider Trading Activity - Stock Titan
Is Ventyx Biosciences Inc. still worth holding after the dipStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ventyx Biosciences Inc. stock recover faster than peersEarnings Growth Report & Pattern Based Trade Signal System - newser.com
How Ventyx Biosciences Inc. stock performs during Fed tightening cycles2025 Pullback Review & AI Driven Stock Reports - newser.com
Ventyx Biosciences at Jefferies Conference: Strategic Focus on NLRP3 Inhibitors - Investing.com Canada
What high frequency data says about Ventyx Biosciences Inc.Quarterly Investment Review & Real-Time Buy Zone Alerts - newser.com
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ventyx Biosciences Inc-Aktie (VTYX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '25 |
Option Exercise |
0.00 |
11,844 |
0 |
2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '25 |
Option Exercise |
0.00 |
4,531 |
0 |
469,113 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 27 '24 |
Sale |
2.36 |
21,119 |
49,841 |
464,582 |
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):